Since its discovery, nearly 90 years, heparin has been used successfully for the treatment of thromboembolic processes. However, therapy with heparin has several important limitations. Most importantly, the poor predictability of its anticoagulant effects has led to the development of the low molecular weight heparins (LMWHs), which are derived from unfractionated heparin and appear to have pharmacologie advantages, require no laboratory monitoring and are more predictable than their parent compounds. LMWHs have been used for several years in the treatment of venous thromboembolic disorders. More recently, the LMWHs have been used to treat patients with acute coronary interventions. As the results of new studies are revealed, we will learn whether the use LMWH can be extended to all disorders where unfractionated heparin is currentlyhe standard therapy. -.

Original languageEnglish (US)
Pages (from-to)1091-1103
Number of pages13
JournalExpert Opinion on Pharmacotherapy
Issue number6
StatePublished - 2000


  • Anticoagulant
  • Low molecular weight heparins
  • Thromboembolic disorders
  • Unfractionated heparin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Low molecular weight heparins'. Together they form a unique fingerprint.

Cite this